Romiplostim for chemotherapy-induced thrombocytopenia in pediatric cancers.
Weekly injections of romiplostim reduced dangerous bleeding in children receiving chemotherapy, providing a safety option for pediatric cancer care.
In this investigator-initiated RCT of 93 pediatric cancer patients, prophylactic romiplostim (3 µg/kg weekly) failed to hasten platelet recovery vs standard care (91.3% vs 88.1%) but significantly reduced grade ≥2 bleeding events (0/46 vs 6/43, p=0.01) and showed a trend toward lower transfusion requirements. These pediatric-specific data expand the evidence base for romiplostim in chemotherapy-induced thrombocytopenia beyond adults, providing safety and efficacy signals relevant to protocol development in pediatric oncology.
What the study was
- Study design
- Randomized controlled trial
- Population
- 93 pediatric cancer patients aged 1-14 years (AML, NHL, solid tumors) receiving myelosuppressive chemotherapy at AIIMS New Delhi; randomized 1:1
- Sample size
- 93
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- British Journal of Cancer
Why it surfaced
Investigator-initiated RCT providing pediatric-specific romiplostim data for CIT; reduced bleeding is a clinically meaningful endpoint even without platelet recovery acceleration; fills pediatric evidence gap.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.